ALEXION - Geography + Label Expansion = Long Term Growth
We expect Soliris (L, Paroxysmal Nocturnal Hemoglobinuria, PNH) sales to remain on a growth trajectory due to geographical expansion and approval into other niche indications. In light of 2Q11 earning release and advancement of various R&D programs, we have analyzed Alexion (ALXN) future prospects. Full details are highlighted in the report, released on July 26, 2011, titled “Geography + Label Expansion = Long Term Growth”.
COMPANIES MENTIONED
ALEXION
ALEXION
More Publications
ALEXION: Soliris’ Label Expansion & Diversification to Perk ALXN Up!
US$ 140.00
April 2012
5 pages
CELGENE - Core Business + Pipeline Investments = Long Term Growth
US$ 140.00
February 2012
9 pages
ALEXION - Great Expectations From Label Expansion
US$ 140.00
September 2011
4 pages
